Introduction Short-and long-acting granulocyte-colony stimulating factors (G-CSFs) are
approved for the reduction of febrile neutropenia. A systematic literature review was …

Purpose Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte
colony-stimulating factors (G-CSFs) have recently been developed. We systematically …

Leukocyte growth factors (LGF), such as filgrastim, pegfilgrastim and sargramostim, have
been used to mitigate the hematologic symptoms of acute radiation syndrome (ARS) after …

Background Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia.
Prophylactic use of recombinant human G-CSF such as daily filgrastim and once-per-cycle …

Introduction Febrile neutropenia (FN) is a serious side-effect of myelosuppressive
chemotherapy. Several clinical trials and observational studies have evaluated the effects of …

Purpose In a recent randomized, open-label trial (ECHELON-1), brentuximab vedotin (BV)
combined with doxorubicin, vinblastine, and dacarbazine (AVD+ BV) decreased the risk of …

Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that may occur in
patients with malignancies receiving myelosuppressive chemotherapy. FN requires early …

Introduction Evidence suggests that many cancer chemotherapy patients who are
candidates for colony-stimulating factor (CSF) prophylaxis do not receive it or receive it …

Background To examine duration of daily filgrastim prophylaxis, and risk and consequences
of chemotherapy-induced neutropenic complications (CINC) requiring inpatient care …

Background PEGylated granulocyte colony-stimulating factor (G-CSF) is a safe alternative to
G-CSF to improve chemotherapy-induced neutropenia (CIN). This superiority has resulted in …